Latigo Biotherapeutics' recent upsized IPO pricing at $18 per share for 19.2 million shares, generating $345.6 million in gross proceeds, serves as the primary driver anchoring trader sentiment around the $1.15B–$1.3B closing market cap range. This outcome aligns closely with the roughly $1.08 billion target valuation referenced in SEC filings and implies moderate first-day trading premiums amid a rebounding biotech IPO window. Positive Phase 2 abdominoplasty data for lead NaV1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, reinforced its positioning as a non-opioid alternative to Vertex's Journavx, supported by $322 million in cumulative funding and a March 2025 Series B at a $525.73 million post-money valuation. Uncertainty around share count dilution, opening-day dynamics, and broader sector multiples sustains secondary probability mass in the $1B–$1.15B bucket, with the August 10 expected close limiting near-term resolution risk.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$1B-$1.15B 22%
$1.3B-$1.45B 1.9%
$1.45B+ 1.9%
<$850M <1%
$1,814 Vol.
$1,814 Vol.
Aug 7, 2026
<$850M
<1%
$850M-$1B
<1%
$1B-$1.15B
22%
$1.15B-$1.3B
-
$1.3B-$1.45B
2%
$1.45B+
2%
No IPO before October 2026
<1%
$1B-$1.15B 22%
$1.3B-$1.45B 1.9%
$1.45B+ 1.9%
<$850M <1%
$1,814 Vol.
$1,814 Vol.
Aug 7, 2026
<$850M
$351 Vol.
<1%
$850M-$1B
$436 Vol.
<1%
$1B-$1.15B
$153 Vol.
22%
$1.15B-$1.3B
$130 Vol.
-
$1.3B-$1.45B
$150 Vol.
2%
$1.45B+
$180 Vol.
2%
No IPO before October 2026
$414 Vol.
<1%
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics' recent upsized IPO pricing at $18 per share for 19.2 million shares, generating $345.6 million in gross proceeds, serves as the primary driver anchoring trader sentiment around the $1.15B–$1.3B closing market cap range. This outcome aligns closely with the roughly $1.08 billion target valuation referenced in SEC filings and implies moderate first-day trading premiums amid a rebounding biotech IPO window. Positive Phase 2 abdominoplasty data for lead NaV1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, reinforced its positioning as a non-opioid alternative to Vertex's Journavx, supported by $322 million in cumulative funding and a March 2025 Series B at a $525.73 million post-money valuation. Uncertainty around share count dilution, opening-day dynamics, and broader sector multiples sustains secondary probability mass in the $1B–$1.15B bucket, with the August 10 expected close limiting near-term resolution risk.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Market Opened: Aug 5, 2026, 5:52 AM ET
Volume
$1,814End Date
Aug 7, 2026Market Opened
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Latigo Biotherapeutics' recent upsized IPO pricing at $18 per share for 19.2 million shares, generating $345.6 million in gross proceeds, serves as the primary driver anchoring trader sentiment around the $1.15B–$1.3B closing market cap range. This outcome aligns closely with the roughly $1.08 billion target valuation referenced in SEC filings and implies moderate first-day trading premiums amid a rebounding biotech IPO window. Positive Phase 2 abdominoplasty data for lead NaV1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, reinforced its positioning as a non-opioid alternative to Vertex's Journavx, supported by $322 million in cumulative funding and a March 2025 Series B at a $525.73 million post-money valuation. Uncertainty around share count dilution, opening-day dynamics, and broader sector multiples sustains secondary probability mass in the $1B–$1.15B bucket, with the August 10 expected close limiting near-term resolution risk.
This market will resolve based on Latigo Biotherapeutics' market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on August 7 (ET). If no such IPO occurs by September 30, 2026, 11:59 PM ET, the market will resolve to "No IPO before October 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$1,814End Date
Aug 7, 2026Market Opened
Aug 5, 2026, 5:52 AM ETResolver
0x69c47De9D...Latigo Biotherapeutics' recent upsized IPO pricing at $18 per share for 19.2 million shares, generating $345.6 million in gross proceeds, serves as the primary driver anchoring trader sentiment around the $1.15B–$1.3B closing market cap range. This outcome aligns closely with the roughly $1.08 billion target valuation referenced in SEC filings and implies moderate first-day trading premiums amid a rebounding biotech IPO window. Positive Phase 2 abdominoplasty data for lead NaV1.8 inhibitor LTG-001, published in the New England Journal of Medicine on July 29, reinforced its positioning as a non-opioid alternative to Vertex's Journavx, supported by $322 million in cumulative funding and a March 2025 Series B at a $525.73 million post-money valuation. Uncertainty around share count dilution, opening-day dynamics, and broader sector multiples sustains secondary probability mass in the $1B–$1.15B bucket, with the August 10 expected close limiting near-term resolution risk.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions